Showing 12,061 - 12,080 results of 37,033 for search '(( 5 ((nn decrease) OR (mean decrease)) ) OR ( 100 ((we decrease) OR (a decrease)) ))', query time: 0.68s Refine Results
  1. 12061

    Image5_Using electronic admission data to monitor temporal trends in local medication use: Experience from an Australian tertiary teaching hospital.tif by Richard J. Woodman (8830580)

    Published 2022
    “…</p><p>Results: Of the 692,522 total admissions, 300,498 (43.4%) had at least one recorded medication. The overall mean number of medications for patients that were medicated increased steadily from a mean (SD) of 5.93 (4.04) in 2007 to 7.21 (4.98) in 2018. …”
  2. 12062
  3. 12063
  4. 12064
  5. 12065
  6. 12066

    DJ-1 knockdown in BV-2 microglia cells enhances LPS-induced death of co-cultured SH-SY5Y neuronal cells. by Chia-Hung Chien (19355)

    Published 2016
    “…Cell viability of SH-SY5Y was evaluated by using MTT assay (A) and methylene blue assay (B). …”
  7. 12067
  8. 12068

    Presentation 1_Case Report: Full recovery in severe ParvovirusB19 myocarditis with DCM phenotype: the impact of rASD and PAB.pptx by T. Logeswaran (21495341)

    Published 2025
    “…The pressure gradient across the PAB ranged from 40 to 45 mmHg, and LVEDD decreased to a mean z-score of +3.5. Within three to six months, LVEDD normalized, and LV-EF increased to a mean of 63% (range: 57%–68%). …”
  9. 12069

    Novel Methods to Generate Active Ingredients-Enriched Ashwagandha Leaves and Extracts - Fig 2 by Sunil C. Kaul (186002)

    Published 2016
    “…<p>(<b>A</b>) Hydroponic cultivation system for Ashwagandha and (<b>B)</b> hydroponically grown leaves are shown. …”
  10. 12070

    Dynamin inhibition affects secretion of other proteins. by Maaike Kockx (154125)

    Published 2014
    “…*<i>P</i><0.05 <i>v</i> Ctrl.</p>…”
  11. 12071

    Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

    Published 2019
    “…The incidence of site reactions decreased with successive infusions.</p><p>Conclusion: The new 16.5% SCIG octanorm was shown to be efficacious in preventing infections in PIDs, and was well tolerated.…”
  12. 12072

    Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

    Published 2019
    “…The incidence of site reactions decreased with successive infusions.</p><p>Conclusion: The new 16.5% SCIG octanorm was shown to be efficacious in preventing infections in PIDs, and was well tolerated.…”
  13. 12073

    Table_2_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

    Published 2022
    “…The incidence of site reactions decreased with successive infusions.</p><p>Conclusion: The new 16.5% SCIG octanorm was shown to be efficacious in preventing infections in PIDs, and was well tolerated.…”
  14. 12074

    Table_1_Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies.do... by Roger H. Kobayashi (6291587)

    Published 2022
    “…The incidence of site reactions decreased with successive infusions.</p><p>Conclusion: The new 16.5% SCIG octanorm was shown to be efficacious in preventing infections in PIDs, and was well tolerated.…”
  15. 12075

    Bubble-Induced Endothelial Microparticles Promote Endothelial Dysfunction by Xuhua Yu (3692524)

    Published 2017
    “…Intracellular ROS production increased while NO production decreased. These negative effects caused by bubble-induced EMPs were remarkably suppressed when EMPs pretreated with surfactant FSN-100. …”
  16. 12076
  17. 12077

    Table_12_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF by Diana C. Esquivel-Franco (5455082)

    Published 2018
    “…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT<sub>1A</sub> receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”
  18. 12078

    Table_13_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF by Diana C. Esquivel-Franco (5455082)

    Published 2018
    “…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT<sub>1A</sub> receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”
  19. 12079

    Image_3_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.TIF by Diana C. Esquivel-Franco (5455082)

    Published 2018
    “…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT<sub>1A</sub> receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”
  20. 12080

    Table_8_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF by Diana C. Esquivel-Franco (5455082)

    Published 2018
    “…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT<sub>1A</sub> receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”